Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Transcription termination factor 1 (TTF1) is a critical nucleolar DNA-binding protein that mediates **site-specific termination of RNA polymerase I transcription** in eukaryotic cells[1][5]. TTF1 recognizes and binds to the "Sal box" terminator motifs flanking the rDNA coding region, ensuring precise cessation of rRNA synthesis and preventing collisions between transcription and replication forks[1][5]. The protein has a multi-domain structure: an N-terminal regulatory domain responsible for oligomerization and auto-inhibition, a central (trans-activation) domain involved in chromatin-specific functions and transcription termination, and a C-terminal DNA-binding domain (Myb/SANT type), homologous to the DNA-binding domains of c-Myb and yeast Reb1p[5]. Besides transcription termination, TTF1 is involved in **transcription initiation**, **chromatin looping and remodeling**, **DNA damage repair**, and **replication fork arrest**. It regulates ribosomal gene activity by promoting nucleosome repositioning, facilitating both gene activation and promoter silencing (via interactions with chromatin remodelers and noncoding RNAs)[2][5]. TTF1's function is essential for ribosomal biogenesis and genomic stability. There is no evidence for direct clinical targeting of TTF1 or its use as a biomarker in human disease outside basic research[4][5]. **Key molecular characteristics:** - Structure: Modular, three-domain protein; C-terminal Myb/SANT domain for DNA binding, central domain for transcription termination. - DNA motif recognition: Binds "Sal box" (11- to 18-bp sequence) upstream and downstream of rDNA units to facilitate precise transcription regulation[1][5]. - No direct links to common drug therapies or biomarker panels. **Notes on ambiguity:** TTF1 is also the commonly used abbreviation for "Thyroid transcription factor 1" (NKX2-1), a homeobox protein used as a lung cancer biomarker. The information here pertains strictly to "Transcription termination factor 1", **RNA polymerase I termination factor**, and not NKX2-1.
Not applicable, as there are no drugs reported to act via TTF1.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Transcription termination factor 1 (TTF1).